Journal: International journal of molecular sciences

Article Title: Cdk4 Regulates Glioblastoma Cell Invasion and Stemness and Is Target of a Notch Inhibitor Plus Resveratrol Combined Treatment.

doi: 10.3390/ijms241210094

Figure Lengend Snippet: Figure 4. Ccnd1 and Cdk4 expression in GBM cells cultured as neurospheres and as a monolayer (A) U87MG and T98G cells were grown as neurospheres (U87MG-N and T98G-N cells, respectively) or as monolayer cultures, and immunoblotting was carried out. β-actin was used as the loading control. Images show the results of one representative experiment out of three. Numbers above the blots

Article Snippet: pcDNA CCND1 HA, pcDNA CCND1 T286A HA, and CDK4R24C expression vectors were from Addgene (Danvers, MA, 01923 USA).

Techniques: Expressing, Cell Culture, Western Blot, Control

Journal: International journal of molecular sciences

Article Title: Cdk4 Regulates Glioblastoma Cell Invasion and Stemness and Is Target of a Notch Inhibitor Plus Resveratrol Combined Treatment.

doi: 10.3390/ijms241210094

Figure Lengend Snippet: Figure 4. Ccnd1 and Cdk4 expression in GBM cells cultured as neurospheres and as a monolayer (A) U87MG and T98G cells were grown as neurospheres (U87MG-N and T98G-N cells, respectively) or as monolayer cultures, and immunoblotting was carried out. β-actin was used as the loading control. Images show the results of one representative experiment out of three. Numbers above the blots

Article Snippet: pcDNA CCND1 HA, pcDNA CCND1 T286A HA, and CDK4R24C expression vectors were from Addgene (Danvers, MA, 01923 USA).

Techniques: Expressing, Cell Culture, Western Blot, Control

Journal: Gynecologic oncology

Article Title: Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas.

doi: 10.1016/j.ygyno.2011.05.021

Figure Lengend Snippet: Fig. 1. STMN1 expression across the morphologic continuum from benign fallopian tube epithelium to invasive serous carcinoma. (A–D) Histological transition from normal epithelium to benign p53 signature, TIC, and invasive HGPSC. (E–H) Intense nuclear p53 staining characterizes the p53 signature, TIC, and invasive tumor; (I–L) Ki-67 staining identifies proliferating cells in the TIC and invasive tumor; (M–P) STMN1 expression is absent from benign epithelium but is strongly induced upon progression to TIC; (Q–T) p27 expression is frequently lost in STMN1-positive lesions. All images are from one representative case.

Article Snippet: FTSECs were immortalized via transduction with retroviral vectors expressing human Telomerase Reverse Transcriptase (hTERT) [20], mutant Cyclin-Dependent Kinase 4 (CDK4R24C) [21], and either dominant negative TP53 [21] or shRNA targeting TP53 [22,23] (Addgene plasmids #1774, 11254, 9058, and 10671; Addgene, Cambridge, MA, USA).

Techniques: Expressing, Staining

Journal: Gynecologic oncology

Article Title: Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas.

doi: 10.1016/j.ygyno.2011.05.021

Figure Lengend Snippet: Fig. 2. Distribution of STMN1-positive cells in benign and malignant fallopian tube epithelium. STMN1 staining was negative (b10% positive cells) in both normal FTE and most p53 signatures, but positive (10–100%) in proliferative p53 signatures, TIC, and HGPSC.

Article Snippet: FTSECs were immortalized via transduction with retroviral vectors expressing human Telomerase Reverse Transcriptase (hTERT) [20], mutant Cyclin-Dependent Kinase 4 (CDK4R24C) [21], and either dominant negative TP53 [21] or shRNA targeting TP53 [22,23] (Addgene plasmids #1774, 11254, 9058, and 10671; Addgene, Cambridge, MA, USA).

Techniques: Staining

Journal: Gynecologic oncology

Article Title: Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas.

doi: 10.1016/j.ygyno.2011.05.021

Figure Lengend Snippet: Fig. 3. STMN1 is expressed in putative precursors to HGPSC. A p53 signature (A–E) and proliferative p53 signature (F–J) from the same patient. The p53 signature is non-proliferative, STMN1-negative, and p27 positive. Proliferative p53 signatures are transitional lesions exhibiting features intermediate between a p53 signature and TIC. Here, mildly increased proliferative activity is accompanied by expression of STMN1 and reduced p27.

Article Snippet: FTSECs were immortalized via transduction with retroviral vectors expressing human Telomerase Reverse Transcriptase (hTERT) [20], mutant Cyclin-Dependent Kinase 4 (CDK4R24C) [21], and either dominant negative TP53 [21] or shRNA targeting TP53 [22,23] (Addgene plasmids #1774, 11254, 9058, and 10671; Addgene, Cambridge, MA, USA).

Techniques: Activity Assay, Expressing